{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Fresh malignant cells are isolated from blood, bone marrow, lymph nodes or other tissue and incubated with recombinant immunotoxins to determine sensitivity to BL22 and other agents to estimate the amount of cancer cells in the body by measuring proteins which fall off cancer cells and go into the blood.","groups":[{"description":"30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.","id":"OG000","title":"BL22 Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Number of Patients Who Developed Neutralizing Antibodies After One or More Cycles of BL22","type":"SECONDARY","unitOfMeasure":"Participants"}